Clinical Trial: Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07245771) titled 'Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity' on Sept. 20.

Brief Summary: Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)

Study Start Date: Nov. 04

Study Type: INTERVENTIONAL

Condition: Obesity &Amp; Overweight

Intervention: DRUG: RN3161...